Bookmark
Forward
QuickView for bimatoprost (compound)
PubChem
| Name: | bimatoprost |
|---|---|
| PubChem Compound ID: | 5311027 |
| Molecular formula: | C25H37NO4 |
| Molecular weight: | 415.566 g/mol |
| Synonyms: |
AGN-192024; Lumigan (TN); 15M; 155206-00-1; 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-; LS-181817; 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-; D02724; 267244-98-4; AGN 192024.
show more » |
DrugBank
Identification
| Name: | bimatoprost |
|---|---|
| Name (isomeric): | DB00905 |
| Drug Type: | small molecule |
| Synonyms: |
AGN 192024
|
| Brand: | Lumigan |
| Category: | Antiglaucomic Agents, Antihypertensive Agents |
| CAS number: | 155206-00-1 |
Pharmacology
| Indication: | For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication. |
|---|---|
| Pharmacology: |
Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity, that is chemically related to prostamide F. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost lowers intraocular pressure (IOP) in humans. Elevated IOP presents a major risk factor for glaucomatou...
show more » |
| Mechanism of Action: |
Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body....
show more » |
| Absorption: | Systemically absorbed when administered to the eye. |
| Protein binding: | Approximately 88% of bimatoprost is bound in human plasma. |
| Biotransformation: | Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites. |
| Route of elimination: | Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces. |
| Half Life: | Elimination half-life is approximately 45 minutes. |
| Clearance: | 1.5 L/hr/kg [Healthy subjects receiving IV administration of 3.12 ug/kg] |
| Toxicity: | In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
